$SYRE
Spyre Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041590 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $688.0K
YoY Change -100.0% 10.08%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.580M $7.439M
YoY Change 23.42% -3.07%
% of Gross Profit
Research & Development $24.66M $17.39M
YoY Change 105.89% 13.09%
% of Gross Profit
Depreciation & Amortization $0.00 $360.0K
YoY Change -100.0% -4.76%
% of Gross Profit
Operating Expenses $18.34M $159.9M
YoY Change -3.13% 593.92%
Operating Profit -$18.34M -$159.2M
YoY Change -2.23% 610.19%
Interest Expense -$24.11M -$57.82M
YoY Change -8471.53% -55696.15%
% of Operating Profit
Other Income/Expense, Net -$21.77M -$57.83M
YoY Change -7076.6% -53153.21%
Pretax Income -$40.10M -$217.1M
YoY Change 117.45% 872.82%
Income Tax $3.000K $7.000K
% Of Pretax Income
Net Earnings -$40.11M -$217.1M
YoY Change 119.96% 872.45%
Net Earnings / Revenue -31552.47%
Basic Earnings Per Share -$9.34 -$2.27
Diluted Earnings Per Share -$9.34 -$2.27
COMMON SHARES
Basic Shares Outstanding 101.2M 65.40M
Diluted Shares Outstanding 4.294M shares 95.57M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $203.6M $235.4M
YoY Change 176.34% 165.84%
Cash & Equivalents $90.59M $235.4M
Short-Term Investments $113.0M $0.00
Other Short-Term Assets $2.200M $2.882M
YoY Change -72.06% -62.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $205.9M $239.9M
YoY Change 150.49% 148.21%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.000K $10.00K
YoY Change -98.8% -98.67%
Total Long-Term Assets $1.316M $3.643M
YoY Change -85.92% -63.79%
TOTAL ASSETS
Total Short-Term Assets $205.9M $239.9M
Total Long-Term Assets $1.316M $3.643M
Total Assets $207.3M $243.5M
YoY Change 126.36% 128.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.50M $2.854M
YoY Change 414.6% 45.76%
Accrued Expenses $15.90M $32.76M
YoY Change 22.35% 140.64%
Deferred Revenue $0.00 $3.271M
YoY Change -100.0% 22.83%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.87M $232.2M
YoY Change 153.83% 1364.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.70M $21.34M
YoY Change
Total Long-Term Liabilities $20.70M $21.34M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $44.87M $232.2M
Total Long-Term Liabilities $20.70M $21.34M
Total Liabilities $65.56M $253.6M
YoY Change 173.05% 1024.5%
SHAREHOLDERS EQUITY
Retained Earnings -$701.2M -$661.1M
YoY Change 72.37% 70.12%
Common Stock $456.0M $453.7M
YoY Change -3.91% -4.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$245.4M -$207.4M
YoY Change
Total Liabilities & Shareholders Equity $207.3M $243.5M
YoY Change 126.36% 128.22%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$40.11M -$217.1M
YoY Change 119.96% 872.45%
Depreciation, Depletion And Amortization $0.00 $360.0K
YoY Change -100.0% -4.76%
Cash From Operating Activities -$34.59M -$16.64M
YoY Change 129.56% -19.49%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$97.63M $6.760M
YoY Change -691.7% 801.33%
Cash From Investing Activities -$97.63M $6.760M
YoY Change -691.73% 801.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.53M 210.0M
YoY Change 9538.46% 390.59%
NET CHANGE
Cash From Operating Activities -34.59M -16.64M
Cash From Investing Activities -97.63M 6.760M
Cash From Financing Activities -12.53M 210.0M
Net Change In Cash -144.8M 200.1M
YoY Change -11226.06% 774.56%
FREE CASH FLOW
Cash From Operating Activities -$34.59M -$16.64M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$34.59M -$16.64M
YoY Change 129.57% -19.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001636282
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37722
dei Entity Registrant Name
EntityRegistrantName
AEGLEA BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4312787
dei Entity Address Address Line1
EntityAddressAddressLine1
221 Crescent Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Building 17
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 102B
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
651-5940
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value Per Share
dei Trading Symbol
TradingSymbol
AGLE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101192921
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235358000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34863000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20848000
CY2023Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1646000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
375000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2882000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6172000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
239886000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
62258000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1317000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3220000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2316000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3430000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
683000
CY2023Q2 us-gaap Assets
Assets
243529000
CY2022Q4 us-gaap Assets
Assets
71144000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2854000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
677000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
164382000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2023Q2 agle Contingent Value Right Liability Current
ContingentValueRightLiabilityCurrent
10500000
CY2022Q4 agle Contingent Value Right Liability Current
ContingentValueRightLiabilityCurrent
0
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4331000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
625000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
930000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
517000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
28427000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12837000
CY2023Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
20810000
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
232234000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14656000
CY2023Q2 agle Contingent Value Right Liability Non Current
ContingentValueRightLiabilityNonCurrent
19000000
CY2022Q4 agle Contingent Value Right Liability Non Current
ContingentValueRightLiabilityNonCurrent
0
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4004000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2341000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2179000
CY2023Q2 us-gaap Liabilities
Liabilities
253575000
CY2022Q4 us-gaap Liabilities
Liabilities
20839000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
8913659
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
81001676
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
81001676
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65350343
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65350343
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
453741000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
475971000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-661127000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-425624000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-207369000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
50305000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
243529000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71144000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
688000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
625000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
886000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1987000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17386000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15373000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
31162000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
32351000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12062000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7675000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17290000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16500000
CY2023Q2 agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130486000
CY2022Q2 agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130486000
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
159934000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
23048000
us-gaap Operating Expenses
OperatingExpenses
178938000
us-gaap Operating Expenses
OperatingExpenses
48851000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-159246000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22423000
us-gaap Operating Income Loss
OperatingIncomeLoss
-178052000
us-gaap Operating Income Loss
OperatingIncomeLoss
-46864000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
350000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
104000
us-gaap Investment Income Net
InvestmentIncomeNet
770000
us-gaap Investment Income Net
InvestmentIncomeNet
139000
CY2023Q2 agle Change In Fair Value Of Forward Contract Liability
ChangeInFairValueOfForwardContractLiability
58170000
CY2022Q2 agle Change In Fair Value Of Forward Contract Liability
ChangeInFairValueOfForwardContractLiability
0
agle Change In Fair Value Of Forward Contract Liability
ChangeInFairValueOfForwardContractLiability
58170000
agle Change In Fair Value Of Forward Contract Liability
ChangeInFairValueOfForwardContractLiability
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-80000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57828000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-57480000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
140000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-217074000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22314000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-235532000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46724000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-29000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
us-gaap Net Income Loss
NetIncomeLoss
-235503000
us-gaap Net Income Loss
NetIncomeLoss
-46759000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.27
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.27
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.63
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95565118
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95565118
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82209032
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82209032
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94917487
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94917487
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73650146
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73650146
CY2023Q2 agle Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
1400000
agle Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
1400000
CY2022Q2 agle Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
0
agle Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
us-gaap Net Income Loss
NetIncomeLoss
-235503000
us-gaap Net Income Loss
NetIncomeLoss
-46759000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
28000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-49000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
31000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-151000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-217064000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22390000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-235444000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46959000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
50305000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1709000
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
10000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
32000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18422000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
33652000
CY2023Q2 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
3768000
CY2023Q2 agle Contingent Value Right Distribution To Common Stockholders
ContingentValueRightDistributionToCommonStockholders
29500000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1775000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-207369000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83941000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
184000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2101000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-13000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-120000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24436000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61657000
CY2022Q2 agle Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering
StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
42873000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2017000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
84157000
us-gaap Profit Loss
ProfitLoss
-235503000
us-gaap Profit Loss
ProfitLoss
-46759000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
781000
us-gaap Share Based Compensation
ShareBasedCompensation
3620000
us-gaap Share Based Compensation
ShareBasedCompensation
4118000
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130486000
agle Change In Fair Value Of Forward Contract Liability
ChangeInFairValueOfForwardContractLiability
58170000
agle Operating Lease Right Of Use Asset Asset And Leasehold Improvement Impairment Loss
OperatingLeaseRightOfUseAssetAssetAndLeaseholdImprovementImpairmentLoss
2580000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-915000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
220000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
191000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-239000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
123000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
23000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-6000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3368000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2419000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2045000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1352000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
575000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-914000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1271000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-336000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-298000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-250000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
189000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-877000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34277000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46936000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3035000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
37000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
475000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
27750000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
54296000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24510000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26509000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
210000000
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
42979000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
184000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
347000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
210002000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42816000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-95000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
200259000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22294000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36416000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16980000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
236675000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39274000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2067000
agle Non Cash Related To Issuance Of Series A Non Voting Convertible Preferred Stock In Connection With Private Placement But Not Yet Paid
NonCashRelatedToIssuanceOfSeriesANonVotingConvertiblePreferredStockInConnectionWithPrivatePlacementButNotYetPaid
12677000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 agle Percentage Of Existing Headcount Reduction
PercentageOfExistingHeadcountReduction
0.83
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-661100000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235400000
CY2023Q2 agle Percentage Of Existing Headcount Reduction
PercentageOfExistingHeadcountReduction
0.83
CY2023Q2 agle Number Of Employees Retained
NumberOfEmployeesRetained
10
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company's financial statements relate to accrued research and development costs; the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of right-of-use lease assets; and estimated cost to complete performance obligations related to revenue recognition.</span></p>
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2023Q2 agle Change In Fair Value Of Forward Contract Liability
ChangeInFairValueOfForwardContractLiability
58200000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18861000
CY2023Q2 agle Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
0
CY2023Q2 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
18861000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
26007000
CY2022Q4 agle Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
1000
CY2022Q4 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
3000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
26005000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20877000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20848000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
25166000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
34000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
25166000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
34000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
330000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
28427000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12837000
CY2023Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
20848000
CY2023Q2 agle Available For Sale Securities Debt Maturities After One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue
0
CY2022Q4 agle Available For Sale Securities Debt Maturities After One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearFairValue
0
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20848000
CY2023Q2 agle Accrued Financing Fees For Pipe
AccruedFinancingFeesForPipe
12677000
CY2022Q4 agle Accrued Financing Fees For Pipe
AccruedFinancingFeesForPipe
0
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
7240000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4589000
CY2023Q2 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
4450000
CY2022Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
6972000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3674000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
946000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
386000
CY2023Q2 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
113300000
CY2023Q2 us-gaap Asset Acquisition Consideration Transferred Transaction Cost
AssetAcquisitionConsiderationTransferredTransactionCost
3200000
CY2023Q2 agle Asset Acquisition Consideration Transferred Fair Value Of Options Assumed
AssetAcquisitionConsiderationTransferredFairValueOfOptionsAssumed
100000
CY2023Q2 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
113300000
CY2023Q2 agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130500000
CY2023Q2 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3000000.0
CY2023Q2 agle Assumed Liabilities
AssumedLiabilities
20200000
CY2023Q2 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
113300000
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
17372312
CY2022Q2 agle Class Of Warrant Or Right Offering Price Of Warrants Or Rights
ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
1.5999
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42900000
CY2022Q2 agle Placement Agent Fees And Offering Costs
PlacementAgentFeesAndOfferingCosts
2100000
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
agle Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised
MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
0.0499
agle Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders
OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
0.0999
agle Period After Notice Received By Company Maximum Ownership Percentage To Be Effective Description
PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription
The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company.
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
63417415
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.30
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
429000
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.96
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1911000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2018000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3620000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4118000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2696000
agle Contract With Customer Liability Revenue Recognized Including Additions
ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions
628000
agle Contract With Customer Liability Deductions Through Contracts Acquired
ContractWithCustomerLiabilityDeductionsThroughContractsAcquired
53000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3271000
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
us-gaap Severance Costs1
SeveranceCosts1
6400000
us-gaap Payments For Restructuring
PaymentsForRestructuring
2200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
1000000.0
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
500000
agle Lease Abandonment Effective Date
LeaseAbandonmentEffectiveDate
2023-06-30
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
900000
us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
1700000

Files In Submission

Name View Source Status
0000950170-23-041590-index-headers.html Edgar Link pending
0000950170-23-041590-index.html Edgar Link pending
0000950170-23-041590.txt Edgar Link pending
0000950170-23-041590-xbrl.zip Edgar Link pending
agle-20230630.htm Edgar Link pending
agle-20230630.xsd Edgar Link pending
agle-ex10_3.htm Edgar Link pending
agle-ex10_4.htm Edgar Link pending
agle-ex10_5.htm Edgar Link pending
agle-ex10_6.htm Edgar Link pending
agle-ex10_7.htm Edgar Link pending
agle-ex10_8.htm Edgar Link pending
agle-ex10_9.htm Edgar Link pending
agle-ex31_1.htm Edgar Link pending
agle-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img116985424_0.jpg Edgar Link pending
img71546535_0.jpg Edgar Link pending
img71546535_1.jpg Edgar Link pending
img71546535_2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
agle-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
agle-20230630_pre.xml Edgar Link unprocessable
agle-20230630_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
agle-20230630_cal.xml Edgar Link unprocessable
agle-20230630_lab.xml Edgar Link unprocessable